The Oncolytic Effect of Recombinant Vesicular Stomatitis Virus Is Enhanced by Expression of the Fusion Cytosine Deaminase/Uracil Phosphoribosyltransferase Suicide Gene

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8366-8376

  Porosnicu, Mercedes ^a   Mian, Abdul ^a   Barber, Glen N ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GAMMA INTERFERON; ONCOLYTIC VIRUS; PRODRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CATALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FUSION GENE; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE GENE; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT;

ANIMALS; CELL LINE, TUMOR; CYTOSINE DEAMINASE; ESCHERICHIA COLI; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PENTOSYLTRANSFERASES; PRODRUGS; RECOMBINANT FUSION PROTEINS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION;

EID: 0346365365     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Greco, O., and Dachs, G. U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol., 187: 22-36, 2001.
2. Martuza, R. L. Conditionally replicating herpes vectors for cancer therapy. J. Clin. Investig., 105: 841-846, 2000.
3. Fernandez, M., Porosnicu, M., Markovic, D., and Barber, G. N. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol., 76: 895-904, 2002.
4. Wagner, R. R., and Rose, J. K. Rhabdoviridae: the viruses and their replication. In: R. J. Whitley, B. N. Fields, D. M. Knipe, and P. M. Howley (eds.), Fields Virology, 3rd ed., pp. 1121-1161. Philadelphia: Lippincott-Raven Publishers, 1996.
5. Johnson, J. E., Schnell, M. J., Buonocore, L., and Rose, J. K. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J. Virol., 71: 5060-5068, 1997.
6. Reif, J. S., Webb, P. A., Monath, T. P., Emerson, J. K., Poland, J. D., Kemp, G. E., and Cholas, G. Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups. Am. J. Trop. Med. Hyg., 36: 177-182, 1987.
7. Barber, G. N. The interferons and cell death: guardians of the cell or accomplices of apoptosis? Semin. Cancer Biol., 10: 103-111, 2000.
8. Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., and Bell, J. C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med., 6: 821-825, 2000.
9. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
10. Mullen, C. A., Kilstrup, M., and Blaese, R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33-37, 1992.
11. Aghi, M., Kramm, C. M., Chou, T. C., Breakefield, X. O., and Chiocca, E. A. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J. Natl. Cancer Inst. (Bethesda), 90: 370-380, 1998.
12. Huber, B. E. Gene therapy strategies for treating neoplastic disease. Ann. N. Y. Acad. Sci., 716: 6-11, discussion 20-22, 1994.
13. Trinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C., and Huber, B. E. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res., 55: 4808-4812, 1995.
14. Kanai, F., Kawakami, T., Hamada, H., Sadata, A., Yoshida, Y., Tanaka, T., Ohashi, M., Tateishi, K., Shiratori, Y., and Omata, M. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res., 58: 1946-1951, 1998.
15. Erbs, P., Regulier, E., Kintz, J., Leroy, P., Poitevin, Y., Exinger, F., Jund, R., and Mehtali, M. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res., 60: 3813-3822, 2000.
16. Adachi, Y., Tamiya, T., Ichikawa, T., Terada, K., Ono, Y., Matsumoto, K., Furuta, T., Hamada, H., and Ohmoto, T. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyl-transferase gene with 5-fluorocytosine. Hum. Gene Ther., 11: 77-89, 2000.
17. Chung-Faye, G. A., Chen, M. J., Green, N. K., Burton, A., Anderson, D., Mautner, V., Searle, P. F., and Kerr, D. J. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyl-transferase. Gene Ther., 8: 1547-1554, 2001.
18. Grad, J. M., Bahlis, N. J., Reis, I., Oshiro, M. M., Dalton, W. S., and Boise, L. H. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 98: 805-813, 2001.
19. Kutubuddin, M., Federoff, H. J., Challita-Eid, P. M., Halterman, M., Day, B., Atkinson, M., Planelles, V., and Rosenblatt, J. D. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood, 93: 643-654, 1999.
20. Tolba, K. A., Bowers, W. J., Muller, J., Housekneckt, V., Giuliano, R. E., Federoff, H. J., and Rosenblatt, J. D. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res., 62: 6545-6551, 2002.
21. Schnell, M. J., Buonocore, L., Whitt, M. A., and Rose, J. K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol., 70: 2318-2323, 1996.
22. Boritz, E., Gerlach, J., Johnson, J. E., and Rose, J. K. Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway. J. Virol., 73: 6937-6945, 1999.
23. Lawson, N. D., Stillman, E. A., Whitt, M. A., and Rose, J. K. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA, 92: 4477-4481, 1995.
24. Kuriyama, S., Kikukawa, M., Masui, K., Okuda, H., Nakatani, T., Sakamoto, T., Yoshiji, H., Fukui, H., Ikenaka, K., Mullen, C. A., and Tsujii, T. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int. J. Cancer, 81: 592-597, 1999.
25. Wang, Z. H., Zagzag, D., Zeng, B., and Kolodny, E. H. In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-α. J. Neuropathol. Exp. Neurol., 58: 847-858, 1999.
26. Nakamura, H., Mullen, J. T., Chandrasekhar, S., Pawlik, T. M., Yoon, S. S., and Tanabe, K. K. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res., 61: 5447-5452, 2001.
27. Miller, C. R., Williams, C. R., Buchsbaum, D. J., and Gillespie, G. Y. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res., 62: 773-780, 2002.
28. Adkins, B., Bu, Y., Cepero, E., and Perez, R. Exclusive Th2 primary effector function in spleens but mixed Th1/Th2 function in lymph nodes of murine neonates. J. Immunol., 164: 2347-2353, 2000.
29. Schnell, M. J., Buonocore, L., Kretzschmar, E., Johnson, E., and Rose, J. K. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl. Acad. Sci. USA, 93: 11359-11365, 1996.
30. Balachandran, S., and Barber, G. N. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life, 50: 135-138, 2000.
31. Beltinger, C., Fulda, S., Kammertoens, T., Meyer, E., Uckert, W., and Debatin, K. M. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of easpases. Proc. Natl. Acad. Sci. USA, 96: 8699-8704, 1999.
32. Berwin, B., Reed, R. C., and Nicchitta, C. V. Virally induced lytic cell death elicits the release of immunogenic GRP94/gp96. J. Biol. Chem., 276: 21083-21088, 2001.
33. Balachandran, S., Porosnicu, M., and Barber, G. N. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol., 75: 3474-3479, 2001.
34. Rose, N. F., Marx, P. A., Luckay, A., Nixon, D. F., Moretto, W. J., Donahoe, S. M., Montefiori, D., Roberts, A., Buonocore, L., and Rose, J. K. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell, 106: 539-549, 2001.
35. Kirn, D., Martuza, R. L., and Zwiebel, J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med., 7: 781-787, 2001.
36. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93: 1831-1835, 1996.
37. Morris, J. C. Enzyme/prodrug-based tumor vaccination: all politics (and immunity) are local. J. Natl. Cancer Inst. (Bethesda), 91: 1986-1989, 1999.
38. Lawrence, T. S., Rehemtulla, A., Ng, E. Y., Wilson, M., Trosko, J. E., and Stetson, P. L. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res., 58: 2588-2593, 1998.
39. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., and Kirn, D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med., 6: 1134-1139, 2000.
40. McCart, J. A., Puhlmann, M., Lee, J., Hu, Y., Libutti, S. K., Alexander, H. R., and Bartlett, D. L. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther., 7: 1217-1223, 2000.
41. Hermiston, T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J. Clin. Investig., 105: 1169-1172, 2000.
42. Consalvo, M., Mullen, C. A., Modesti, A., Musiani, P., Allione, A., Cavallo, F., Giovarelli, M., and Forni, G. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J. Immunol., 154: 5302-5312, 1995.
43. Ju, D. W., Tao, Q., Cheng, D. S., Zhang, W., Zhang, M., Hamada, H., and Cao, X. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Ther., 7: 329-338, 2000.
44. Pierrefite-Carle, V., Baque, P., Gavelli, A., Mala, M., Chazal, M., Gugenheim, J., Bourgeon, A., Milano, G., Staccini, P., and Rossi, B. Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect. J. Natl. Cancer Inst. (Bethesda), 91: 2014-2019, 1999.
45. Dilber, M. S., and Smith, C. I. Suicide genes and bystander killing: local and distant effects. Gene Ther., 4: 273-274, 1997.
46. Ramesh, R., Marrogi, A. J., Munshi, A., Abboud, C. N., and Freeman, S. M. In vivo analysis of the "bystander effect": a cytokine cascade. Exp. Hematol., 24: 829-838, 1996.
47. Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T., and Good, S. S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA. 91: 8302-8306, 1994.
48. Fuchs, E. J., and Matzinger, P. Is cancer dangerous to the immune system? Semin. Immunol., 8: 271-280, 1996.
49. Matzinger, P. An innate sense of danger. Semin. Immunol., 10: 399-415, 1998.
50. Kievit, E., Nyati, M. K., Ng, E., Stegman, L. D., Parsels, J., Ross, B. D., Rehemtulla, A., and Lawrence, T. S. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res., 60: 6649-6655, 2000.